Initial results from the trial indicate it was well-tolerated and promoted a good immune response.
A COVID-19 vaccine for children aged 5 to 11 years is 1 step closer to reality with the release of topline data from Pfizer/BioNTech for their vaccine, named COMIRNATY following the US Food and Drug Administration (FDA) approval of the vaccine for people aged 16 and older.1
The results from the Phase 2/3 trial showed the vaccine was safe, well tolerated, and promoted a robust response.
The trial had 2268 patients aged 5 to 11 years. They were given a 10 µg dose, which is smaller than the dose given to people aged 12 and old, in a 2-dose regimen. Following the second dose, the geometric mean titers taken showed strong immune responses a month after receiving both doses.
The geometric mean titers also compared well to those seen in participants aged 16 to 25 years who had been used as the control group for the analysis. Overall, the side effects were comparable to those seen in the control group participants.
Pfizer/BioNTech plan to share these results with the FDA and other regulatory bodies around the world in the immediate future. Topline data from the 2 to 5 years of age and 6 months to 2 years of age cohorts are expected to be released at some point in the fourth quarter.
Reference
1. Pfizer. Pfizer and BioNTech announce positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years. Published September 20, 2021. Accessed September 20, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.